Revance

RVNC NASDAQ
11.55
-0.13
-1.11%
已收盘, 17:55 06/24 EDT
开盘
11.64
昨收
11.68
最高
11.76
最低
11.47
成交量
31.09万
成交均量(3M)
36.21万
52周最高
30.60
52周最低
10.37
换手率
0.71%
市值
5.08亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Revance RVNC股票价格,Revance股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Revance Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical. It is engaged in the clinical development for RT002 injectable. RT002 injectable utilizes botulinum toxin-peptide complex in a saline-based formulation. In RT002 injectable, the peptide interacts with both extracellular structures and cell surface receptors in the targeted muscle. This interaction restricts the toxin molecule to the target site and reduces unwanted spread to other neighboring muscles. It is focusing on developing RT002 for the treatment of glabellar lines, cervical dystonia and plantar fasciitis.
展开 >

最近浏览

名称
价格
涨跌幅